This week Chemotargets announces the launch of CLARITY PV, a new product for translational safety and pharmacovigilance professionals.
Barcelona, July 5th, 2021. Chemotargets launches CLARTY PV, a new web-based platform for translational safety and pharmacovigilance. CLARITY PV (https://claritypv.com) contains highly-curated structured and integrated data covering the entire safety lifetime of a drug, from safety pharmacology, through preclinical toxicology and clinical safety, up to post-marketing reports, allowing for a seamless connection and traceability of safety signals across all drug discovery phases. CLARITY PV has been thoroughly validated to alert on potential drug safety signals, in most cases identified months, and even years, in advance to any conference communication, company statement or risk awareness from pharmacovigilance committees. The platform includes new analytics tools and reporting options to assist the user in performing periodic safety surveillance of the drugs and drug classes of interest.
Clarity PV will be officially presented for the first time this week at the 48th Annual Meeting of the Japanese Society of Toxicology.
Please, contact email@example.com to request a demo license for a trial period.